{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T02:21:10Z","timestamp":1793845270675,"version":"4.6.1"},"reference-count":148,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,4,10]],"date-time":"2025-04-10T00:00:00Z","timestamp":1744243200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Blood Reviews"],"published-print":{"date-parts":[[2025,7]]},"DOI":"10.1016\/j.blre.2025.101287","type":"journal-article","created":{"date-parts":[[2025,4,11]],"date-time":"2025-04-11T06:51:40Z","timestamp":1744354300000},"page":"101287","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"special_numbering":"C","title":["Practical guidance on the prevention and management of infection in multiple myeloma patients: A case-based approach"],"prefix":"10.1016","volume":"72","author":[{"given":"A.","family":"Kannan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.","family":"Jeffrey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Misbah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.","family":"Ramasamy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.blre.2025.101287_bb0005","doi-asserted-by":"crossref","DOI":"10.1016\/j.leukres.2024.107544","article-title":"Multiple myeloma and infections in the era of novel treatment modalities","volume":"143","author":"Akhmedov","year":"2024","journal-title":"Leuk Res"},{"issue":"36","key":"10.1016\/j.blre.2025.101287_bb0010","doi-asserted-by":"crossref","first-page":"9219","DOI":"10.1200\/JCO.2005.03.2086","article-title":"Early mortality after diagnosis of multiple myeloma: analysis of patients entered onto the United kingdom Medical Research Council trials between 1980 and 2002--Medical Research Council Adult Leukaemia Working Party","volume":"23","author":"Augustson","year":"2005","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.blre.2025.101287_bb0015","doi-asserted-by":"crossref","first-page":"e143","DOI":"10.1016\/S2352-3026(21)00283-0","article-title":"Consensus guidelines and recommendations for infection prevention in multiple myeloma: a report from the international myeloma working group","volume":"9","author":"Raje","year":"2022","journal-title":"The Lancet Haematology"},{"key":"10.1016\/j.blre.2025.101287_bb0020","first-page":"13","article-title":"Editorial: T-cell directed therapies in multiple myeloma","author":"Richter","year":"2023","journal-title":"Frontiers in Oncology"},{"issue":"7","key":"10.1016\/j.blre.2025.101287_bb0025","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1016\/j.clml.2021.02.002","article-title":"Epidemiology and risks of infections in patients with multiple myeloma managed with new generation therapies","volume":"21","author":"Lim","year":"2021","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"1","key":"10.1016\/j.blre.2025.101287_bb0030","doi-asserted-by":"crossref","first-page":"107","DOI":"10.3324\/haematol.2014.107714","article-title":"Multiple myeloma and infections: a population-based study on 9253 multiple myeloma patients","volume":"100","author":"Blimark","year":"2015","journal-title":"Haematologica"},{"issue":"3","key":"10.1016\/j.blre.2025.101287_bb0035","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1038\/s41375-023-02105-6","article-title":"Predictors of early morbidity and mortality in newly diagnosed multiple myeloma: data from five randomized, controlled, phase III trials in 3700 patients","volume":"38","author":"Mai","year":"2024","journal-title":"Leukemia"},{"issue":"10297","key":"10.1016\/j.blre.2025.101287_bb0040","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1016\/S0140-6736(21)00933-8","article-title":"Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b\/2 open-label study","volume":"398","author":"Berdeja","year":"2021","journal-title":"The Lancet"},{"issue":"6","key":"10.1016\/j.blre.2025.101287_bb0045","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1200\/JCO.22.00842","article-title":"Ciltacabtagene Autoleucel, an anti-B-cell maturation antigen chimeric antigen receptor T-cell therapy, for relapsed\/refractory multiple myeloma: CARTITUDE-1 2-year follow-up","volume":"41","author":"Martin","year":"2023","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.blre.2025.101287_bb0050","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1038\/s41408-022-00629-1","article-title":"Incidence and management of CAR-T neurotoxicity in patients with multiple myeloma treated with ciltacabtagene autoleucel in CARTITUDE studies","volume":"12","author":"Cohen","year":"2022","journal-title":"Blood Cancer J"},{"issue":"4","key":"10.1016\/j.blre.2025.101287_bb0055","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1056\/NEJMoa2303379","article-title":"Cilta-cel or standard care in Lenalidomide-refractory multiple myeloma","volume":"389","author":"San-Miguel","year":"2023","journal-title":"N Engl J Med"},{"issue":"9","key":"10.1016\/j.blre.2025.101287_bb0060","doi-asserted-by":"crossref","first-page":"2259","DOI":"10.1038\/s41591-023-02528-9","article-title":"Elranatamab in relapsed or refractory multiple myeloma: phase 2 MagnetisMM-3 trial results","volume":"29","author":"Lesokhin","year":"2023","journal-title":"Nat Med"},{"issue":"10","key":"10.1016\/j.blre.2025.101287_bb0065","doi-asserted-by":"crossref","first-page":"1477","DOI":"10.1038\/s41409-022-01756-w","article-title":"Infectious complications, immune reconstitution, and infection prophylaxis after CD19 chimeric antigen receptor T-cell therapy","volume":"57","author":"Wudhikarn","year":"2022","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.blre.2025.101287_bb0070","doi-asserted-by":"crossref","DOI":"10.1016\/j.critrevonc.2023.104134","article-title":"Infections in haematology patients treated with CAR-T therapies: a systematic review and meta-analysis","volume":"192","author":"Reynolds","year":"2023","journal-title":"Crit Rev Oncol Hematol"},{"issue":"24","key":"10.1016\/j.blre.2025.101287_bb0075","doi-asserted-by":"crossref","first-page":"6109","DOI":"10.1182\/bloodadvances.2022008320","article-title":"Early cytopenias and infections after standard of care idecabtagene vicleucel in relapsed or refractory multiple myeloma","volume":"6","author":"Logue","year":"2022","journal-title":"Blood Adv"},{"issue":"21","key":"10.1016\/j.blre.2025.101287_bb0080","doi-asserted-by":"crossref","first-page":"4053","DOI":"10.1182\/blood.V116.21.4053.4053","article-title":"Monoclonal Gammopathy of undetermined significance and risk of infections: a population-based study","volume":"116","author":"Kristinsson","year":"2010","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.blre.2025.101287_bb0085","doi-asserted-by":"crossref","DOI":"10.1038\/nrdp.2017.46","article-title":"Multiple myeloma","volume":"3","author":"Kumar","year":"2017","journal-title":"Nature Reviews Disease Primers"},{"key":"10.1016\/j.blre.2025.101287_bb0090","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.738915","article-title":"Secondary immunodeficiency in hematological malignancies: focus on multiple myeloma and chronic lymphocytic leukemia","volume":"12","author":"Allegra","year":"2021","journal-title":"Front Immunol"},{"issue":"8","key":"10.1016\/j.blre.2025.101287_bb0095","doi-asserted-by":"crossref","first-page":"1570","DOI":"10.1080\/10428190500472503","article-title":"Immune parameters in multiple myeloma patients: influence of treatment and correlation with opportunistic infections","volume":"47","author":"Sch\u00fctt","year":"2006","journal-title":"Leuk Lymphoma"},{"issue":"2","key":"10.1016\/j.blre.2025.101287_bb0100","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1111\/j.1365-2141.1983.tb02021.x","article-title":"Abnormal monoclonal antibody-defined helper\/suppressor T-cell subpopulations in multiple myeloma: relationship to treatment and clinical stage","volume":"53","author":"Mills","year":"1983","journal-title":"Br J Haematol"},{"issue":"2","key":"10.1016\/j.blre.2025.101287_bb0105","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.blre.2014.01.004","article-title":"Changing treatment paradigms for patients with plasma cell myeloma: impact upon immune determinants of infection","volume":"28","author":"Teh","year":"2014","journal-title":"Blood Rev"},{"issue":"13","key":"10.1016\/j.blre.2025.101287_bb0110","doi-asserted-by":"crossref","first-page":"1362","DOI":"10.1056\/NEJMoa054494","article-title":"Prevalence of monoclonal gammopathy of undetermined significance","volume":"354","author":"Kyle","year":"2006","journal-title":"N Engl J Med"},{"issue":"11","key":"10.1016\/j.blre.2025.101287_bb0115","first-page":"1172","article-title":"The impact of M-component type and immunoglobulin concentration on the risk of malignant transformation in patients with monoclonal gammopathy of undetermined significance","volume":"86","author":"Gregersen","year":"2001","journal-title":"Haematologica"},{"issue":"2","key":"10.1016\/j.blre.2025.101287_bb0120","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1111\/j.1600-0609.1998.tb01075.x","article-title":"The risk of bacteremia in patients with monoclonal gammopathy of undetermined significance","volume":"61","author":"Gregersen","year":"1998","journal-title":"Eur J Haematol"},{"issue":"1","key":"10.1016\/j.blre.2025.101287_bb0125","doi-asserted-by":"crossref","first-page":"21","DOI":"10.4065\/78.1.21","article-title":"Review of 1027 patients with newly diagnosed multiple myeloma","volume":"78","author":"Kyle","year":"2003","journal-title":"Mayo Clin Proc"},{"issue":"12","key":"10.1016\/j.blre.2025.101287_bb0130","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0188988","article-title":"Immunoparesis in newly diagnosed multiple myeloma patients: effects on overall survival and progression free survival in the Danish population","volume":"12","author":"S\u00f8rrig","year":"2017","journal-title":"PloS One"},{"issue":"3","key":"10.1016\/j.blre.2025.101287_bb0135","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1038\/s41375-021-01506-9","article-title":"Inflammation and infection in plasma cell disorders: how pathogens shape the fate of patients","volume":"36","author":"Caro","year":"2022","journal-title":"Leukemia"},{"issue":"4","key":"10.1016\/j.blre.2025.101287_bb0140","doi-asserted-by":"crossref","first-page":"294","DOI":"10.7326\/0003-4819-129-4-199808150-00005","article-title":"Prevalence of monoclonal gammopathies in patients with hepatitis C virus infection","volume":"129","author":"Andreone","year":"1998","journal-title":"Ann Intern Med"},{"issue":"6","key":"10.1016\/j.blre.2025.101287_bb0145","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1111\/j.1572-0241.2002.05668.x","article-title":"Role of helicobacter pylori infection in the incidence and clinical course of monoclonal gammopathy of undetermined significance","volume":"97","author":"Malik","year":"2002","journal-title":"Am J Gastroenterol"},{"issue":"4 Suppl 3","key":"10.1016\/j.blre.2025.101287_bb0150","article-title":"Prevalence of monoclonal gammopathy in HIV patients in 2014","volume":"17","author":"Genet","year":"2014","journal-title":"J Int AIDS Soc"},{"issue":"10","key":"10.1016\/j.blre.2025.101287_bb0155","doi-asserted-by":"crossref","DOI":"10.1042\/BSR20190284","article-title":"Epstein-Barr virus infection is associated with clinical characteristics and poor prognosis of multiple myeloma","volume":"39","author":"Xia","year":"2019","journal-title":"Biosci Rep"},{"issue":"2","key":"10.1016\/j.blre.2025.101287_bb0160","doi-asserted-by":"crossref","first-page":"270","DOI":"10.3109\/10428194.2011.610013","article-title":"High prevalence of hepatitis B virus infection in multiple myeloma","volume":"53","author":"Huang","year":"2012","journal-title":"Leuk Lymphoma"},{"issue":"6","key":"10.1016\/j.blre.2025.101287_bb0175","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.3390\/cancers13061353","article-title":"Immune system alterations in multiple myeloma: molecular mechanisms and therapeutic strategies to reverse immunosuppression","volume":"13","author":"D\u00edaz-Tejedor","year":"2021","journal-title":"Cancers"},{"key":"10.1016\/j.blre.2025.101287_bb0190","article-title":"Aging-associated immune system changes in multiple myeloma: the dark side of the moon","volume":"29","author":"Visram","year":"2021","journal-title":"Cancer Treat Res Commun"},{"issue":"3","key":"10.1016\/j.blre.2025.101287_bb0205","doi-asserted-by":"crossref","first-page":"359","DOI":"10.3390\/cells11030359","article-title":"Interconnections between Inflammageing and Immunosenescence during ageing","volume":"11","author":"Teissier","year":"2022","journal-title":"Cells"},{"issue":"2","key":"10.1016\/j.blre.2025.101287_bb0210","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1007\/s12016-021-08909-7","article-title":"Immunosenescence, Inflammaging, and frailty: role of myeloid cells in age-related diseases","volume":"64","author":"Bleve","year":"2023","journal-title":"Clin Rev Allergy Immunol"},{"issue":"4","key":"10.1016\/j.blre.2025.101287_bb0165","doi-asserted-by":"crossref","first-page":"948","DOI":"10.1046\/j.1365-2141.1999.01455.x","article-title":"Monocyte dysfunction in patients with multiple myeloma and lymphoplasmacytic disorders is related to serum paraprotein levels","volume":"105","author":"Mainwaring","year":"1999","journal-title":"Br J Haematol"},{"issue":"5","key":"10.1016\/j.blre.2025.101287_bb0170","doi-asserted-by":"crossref","first-page":"1487","DOI":"10.1016\/j.jaci.2015.10.018","article-title":"IL-10 mediates plasmacytosis-associated immunodeficiency by inhibiting complement-mediated neutrophil migration","volume":"137","author":"Kulkarni","year":"2016","journal-title":"J Allergy Clin Immunol"},{"issue":"1","key":"10.1016\/j.blre.2025.101287_bb0180","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1186\/s12885-021-08280-y","article-title":"Measuring the global, regional, and national burden of multiple myeloma from 1990 to 2019","volume":"21","author":"Zhou","year":"2021","journal-title":"BMC Cancer"},{"key":"10.1016\/j.blre.2025.101287_bb0185","doi-asserted-by":"crossref","DOI":"10.1182\/bloodadvances.2024015680","article-title":"Immune-aging is linked to clinical malignancy, racial ancestry and vaccine responses in myeloma","author":"Potdar","year":"2025","journal-title":"Blood Adv"},{"issue":"5","key":"10.1016\/j.blre.2025.101287_bb0195","first-page":"442","article-title":"Type 2 diabetes and its impact on the immune system","volume":"16","author":"Berbudi","year":"2020","journal-title":"Curr Diabetes Rev"},{"key":"10.1016\/j.blre.2025.101287_bb0200","first-page":"423","article-title":"Multiple myeloma in the very elderly patient: challenges and solutions","volume":"11","author":"Willan","year":"2016","journal-title":"Clin Interv Aging"},{"issue":"4","key":"10.1016\/j.blre.2025.101287_bb0215","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1038\/s41408-022-00652-2","article-title":"A simple score to predict early severe infections in patients with newly diagnosed multiple myeloma","volume":"12","author":"Encinas","year":"2022","journal-title":"Blood Cancer J"},{"issue":"6","key":"10.1016\/j.blre.2025.101287_bb0220","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.1038\/s41375-018-0133-x","article-title":"A predictive model for risk of early grade\u22653 infection in patients with multiple myeloma not eligible for transplant: analysis of the FIRST trial","volume":"32","author":"Dumontet","year":"2018","journal-title":"Leukemia"},{"issue":"22","key":"10.1016\/j.blre.2025.101287_bb0225","doi-asserted-by":"crossref","first-page":"2104","DOI":"10.1056\/NEJMoa1817249","article-title":"Daratumumab plus Lenalidomide and dexamethasone for untreated myeloma","volume":"380","author":"Facon","year":"2019","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.blre.2025.101287_bb0230","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1111\/bjh.13532","article-title":"Risks, severity and timing of infections in patients with multiple myeloma: a longitudinal cohort study in the era of immunomodulatory drug therapy","volume":"171","author":"Teh","year":"2015","journal-title":"Br J Haematol"},{"issue":"4","key":"10.1016\/j.blre.2025.101287_bb0235","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1038\/nri.2017.1","article-title":"Immune regulation by glucocorticoids","volume":"17","author":"Cain","year":"2017","journal-title":"Nat Rev Immunol"},{"issue":"5","key":"10.1016\/j.blre.2025.101287_bb0240","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1002024","article-title":"Common infections in patients prescribed systemic glucocorticoids in primary care: a population-based cohort study","volume":"13","author":"Fardet","year":"2016","journal-title":"PLoS Med"},{"issue":"1","key":"10.1016\/j.blre.2025.101287_bb0245","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S1470-2045(09)70284-0","article-title":"Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomised controlled trial","volume":"11","author":"Rajkumar","year":"2010","journal-title":"Lancet Oncol"},{"issue":"1","key":"10.1016\/j.blre.2025.101287_bb0250","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1038\/s41375-018-0195-9","article-title":"Bortezomib-based induction therapy with high or low-dose dexamethasone in newly diagnosed, transplant-eligible multiple myeloma","volume":"33","author":"Mai","year":"2019","journal-title":"Leukemia"},{"key":"10.1016\/j.blre.2025.101287_bb0255","series-title":"Multiple myeloma: pharmacologic therapies: refining the evidence: randomized trials in multiple myeloma","author":"Salomon Manier","year":"2025"},{"key":"10.1016\/j.blre.2025.101287_bb0260","article-title":"Tumor and microenvironmental mechanisms of resistance to immunomodulatory drugs in multiple myeloma","volume":"12","author":"Chen","year":"2022","journal-title":"Front Oncol"},{"issue":"28","key":"10.1016\/j.blre.2025.101287_bb0265","doi-asserted-by":"crossref","first-page":"46593","DOI":"10.18632\/oncotarget.16235","article-title":"Lenalidomide and the risk of serious infection in patients with multiple myeloma: a systematic review and meta-analysis","volume":"8","author":"Ying","year":"2017","journal-title":"Oncotarget"},{"issue":"3","key":"10.1016\/j.blre.2025.101287_bb0270","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1182\/blood-2009-05-221077","article-title":"Immunomodulatory derivatives induce PU.1 down-regulation, myeloid maturation arrest, and neutropenia","volume":"115","author":"Pal","year":"2010","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.blre.2025.101287_bb0275","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1111\/j.1600-0609.2012.01814.x","article-title":"Infection complications in an unselected cohort of patients with multiple myeloma treated with lenalidomide combinations","volume":"89","author":"Caravita","year":"2012","journal-title":"Eur J Haematol"},{"issue":"7","key":"10.1016\/j.blre.2025.101287_bb0280","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13071686","article-title":"Emerging therapeutic strategies to overcome drug resistance in multiple myeloma","volume":"13","author":"Davis","year":"2021","journal-title":"Cancers"},{"issue":"2","key":"10.1016\/j.blre.2025.101287_bb0285","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0211927","article-title":"Infectious complications and NK cell depletion following daratumumab treatment of multiple myeloma","volume":"14","author":"Nahi","year":"2019","journal-title":"PloS One"},{"issue":"14","key":"10.1016\/j.blre.2025.101287_bb0290","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1056\/NEJMoa1607751","article-title":"Daratumumab, Lenalidomide, and dexamethasone for multiple myeloma","volume":"375","author":"Dimopoulos","year":"2016","journal-title":"N Engl J Med"},{"issue":"Supplement_1","key":"10.1016\/j.blre.2025.101287_bb0295","article-title":"Updated Meta-analysis of randomized controlled trials to evaluate the incidence of infection and pneumonia in patients with multiple myeloma treated with Daratumumab","volume":"134","author":"Htut","year":"2019","journal-title":"Blood"},{"issue":"10441","key":"10.1016\/j.blre.2025.101287_bb0300","doi-asserted-by":"crossref","first-page":"2307","DOI":"10.1016\/S0140-6736(24)00850-X","article-title":"Contribution of vaccination to improved survival and health: modelling 50 years of the expanded Programme on immunization","volume":"403","author":"Shattock","year":"2024","journal-title":"The Lancet"},{"issue":"Suppl. 2","key":"10.1016\/j.blre.2025.101287_bb0305","first-page":"S46","article-title":"Prevention of infections including vaccination strategies in multiple myeloma","volume":"98","author":"Ludwig","year":"2023","journal-title":"Am J Hematol"},{"issue":"9","key":"10.1016\/j.blre.2025.101287_bb0310","doi-asserted-by":"crossref","first-page":"988","DOI":"10.1016\/S1473-3099(19)30163-X","article-title":"Immunogenicity and safety of the adjuvanted recombinant zoster vaccine in adults with haematological malignancies: a phase 3, randomised, clinical trial and post-hoc efficacy analysis","volume":"19","author":"Dagnew","year":"2019","journal-title":"Lancet Infect Dis"},{"issue":"11","key":"10.1016\/j.blre.2025.101287_bb0315","doi-asserted-by":"crossref","first-page":"4144","DOI":"10.1080\/21645515.2021.1953346","article-title":"Adjuvanted recombinant zoster vaccine in adult autologous stem cell transplant recipients: polyfunctional immune responses and lessons for clinical practice","volume":"17","author":"Stadtmauer","year":"2021","journal-title":"Hum Vaccin Immunother"},{"issue":"7","key":"10.1016\/j.blre.2025.101287_bb0320","doi-asserted-by":"crossref","first-page":"e285","DOI":"10.3324\/haematol.2014.116772","article-title":"Efficacy of single versus boost vaccination against influenza virus in patients with multiple myeloma","volume":"100","author":"Hahn","year":"2015","journal-title":"Haematologica"},{"issue":"Supplement 1","key":"10.1016\/j.blre.2025.101287_bb0325","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2023-180096","article-title":"Immune responses after one versus two influenza a\/B vaccinations in patients with multiple myeloma","volume":"142","author":"Enssle","year":"2023","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.blre.2025.101287_bb0330","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1182\/bloodadvances.2020003880","article-title":"Tandem high-dose influenza vaccination is associated with more durable serologic immunity in patients with plasma cell dyscrasias","volume":"5","author":"Branagan","year":"2021","journal-title":"Blood Adv"},{"issue":"Supplement 1","key":"10.1016\/j.blre.2025.101287_bb0335","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2024-202102","article-title":"A randomized trial demonstrates a 3-shot flu vaccine series improves protection over a single shot in multiple myeloma","volume":"144","author":"Hofmeister","year":"2024","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.blre.2025.101287_bb0340","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1056\/NEJMc2406750","article-title":"Influenza vaccination strategies in patients with hematologic Cancer","volume":"392","author":"Hall","year":"2025","journal-title":"N Engl J Med"},{"issue":"26","key":"10.1016\/j.blre.2025.101287_bb0345","doi-asserted-by":"crossref","first-page":"3674","DOI":"10.1182\/blood.2021011904","article-title":"Low neutralizing antibody responses against SARS-CoV-2 in older patients with myeloma after the first BNT162b2 vaccine dose","volume":"137","author":"Terpos","year":"2021","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.blre.2025.101287_bb0350","doi-asserted-by":"crossref","first-page":"e389","DOI":"10.1016\/S2352-3026(21)00110-1","article-title":"Response to first vaccination against SARS-CoV-2 in patients with multiple myeloma","volume":"8","author":"Bird","year":"2021","journal-title":"Lancet Haematol."},{"issue":"3","key":"10.1016\/j.blre.2025.101287_bb0355","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1111\/bjh.18066","article-title":"Immune response to COVID-19 vaccination is attenuated by poor disease control and antimyeloma therapy with vaccine driven divergent T-cell response","volume":"197","author":"Ramasamy","year":"2022","journal-title":"Br J Haematol"},{"issue":"8","key":"10.1016\/j.blre.2025.101287_bb0360","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1016\/j.ccell.2021.06.014","article-title":"Highly variable SARS-CoV-2 spike antibody responses to two doses of COVID-19 RNA vaccination in patients with multiple myeloma","volume":"39","author":"Van Oekelen","year":"2021","journal-title":"Cancer Cell"},{"issue":"26","key":"10.1016\/j.blre.2025.101287_bb0365","doi-asserted-by":"crossref","first-page":"3057","DOI":"10.1200\/JCO.21.02257","article-title":"Determinants of neutralizing antibody response after SARS CoV-2 vaccination in patients with myeloma","volume":"40","author":"Nooka","year":"2022","journal-title":"J Clin Oncol"},{"issue":"12","key":"10.1016\/j.blre.2025.101287_bb0370","doi-asserted-by":"crossref","first-page":"e934","DOI":"10.1016\/S2352-3026(21)00278-7","article-title":"COVID-19 vaccination in patients with multiple myeloma: a consensus of the European myeloma network","volume":"8","author":"Ludwig","year":"2021","journal-title":"Lancet Haematol"},{"issue":"8","key":"10.1016\/j.blre.2025.101287_bb0375","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1038\/s41408-021-00530-3","article-title":"The neutralizing antibody response post COVID-19 vaccination in patients with myeloma is highly dependent on the type of anti-myeloma treatment","volume":"11","author":"Terpos","year":"2021","journal-title":"Blood Cancer J"},{"issue":"5","key":"10.1016\/j.blre.2025.101287_bb0380","doi-asserted-by":"crossref","first-page":"1426","DOI":"10.1158\/1078-0432.CCR-11-1221","article-title":"Lenalidomide-induced immunomodulation in multiple myeloma: impact on vaccines and antitumor responses","volume":"18","author":"Noonan","year":"2012","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.blre.2025.101287_bb0385","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/j.intimp.2017.05.007","article-title":"Lenalidomide acts as an adjuvant for HCV DNA vaccine","volume":"48","author":"Borhani","year":"2017","journal-title":"Int Immunopharmacol"},{"issue":"18","key":"10.1016\/j.blre.2025.101287_bb0390","doi-asserted-by":"crossref","first-page":"3131","DOI":"10.1016\/j.ejca.2009.08.010","article-title":"Antiviral prophylaxis in haematological patients: systematic review and meta-analysis","volume":"45","author":"Yahav","year":"2009","journal-title":"Eur J Cancer"},{"issue":"8","key":"10.1016\/j.blre.2025.101287_bb0395","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1086\/605664","article-title":"Infections in patients with multiple myeloma in the era of high-dose therapy and novel agents","volume":"49","author":"Nucci","year":"2009","journal-title":"Clin Infect Dis"},{"issue":"9","key":"10.1016\/j.blre.2025.101287_bb0400","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1016\/j.clml.2024.05.002","article-title":"Risk of infection in patients with multiple myeloma treated with T-cell redirecting approaches: a call out for clinicians","volume":"24","author":"Lupia","year":"2024","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"10454","key":"10.1016\/j.blre.2025.101287_bb0405","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1016\/S0140-6736(24)01357-6","article-title":"Antivirals for post-exposure prophylaxis of influenza: a systematic review and network meta-analysis","volume":"404","author":"Zhao","year":"2024","journal-title":"The Lancet"},{"issue":"10","key":"10.1016\/j.blre.2025.101287_bb0410","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1056\/NEJMoa044097","article-title":"Levofloxacin to prevent bacterial infection in patients with cancer and neutropenia","volume":"353","author":"Bucaneve","year":"2005","journal-title":"N Engl J Med"},{"issue":"10","key":"10.1016\/j.blre.2025.101287_bb0415","doi-asserted-by":"crossref","first-page":"988","DOI":"10.1056\/NEJMoa050078","article-title":"Antibacterial prophylaxis after chemotherapy for solid tumors and lymphomas","volume":"353","author":"Cullen","year":"2005","journal-title":"N Engl J Med"},{"issue":"24","key":"10.1016\/j.blre.2025.101287_bb0420","doi-asserted-by":"crossref","first-page":"2769","DOI":"10.2165\/00003495-200363240-00008","article-title":"Levofloxacin: a review of its use in the treatment of bacterial infections in the United States","volume":"63","author":"Croom","year":"2003","journal-title":"Drugs"},{"issue":"62","key":"10.1016\/j.blre.2025.101287_bb0425","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3310\/hta23620","article-title":"Prophylactic levofloxacin to prevent infections in newly diagnosed symptomatic myeloma: the TEAMM RCT","volume":"23","author":"Drayson","year":"2019","journal-title":"Health Technol Assess"},{"issue":"3","key":"10.1016\/j.blre.2025.101287_bb0430","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1200\/JCO.1998.16.3.1179","article-title":"Efficacy of quinolone prophylaxis in neutropenic cancer patients: a meta-analysis","volume":"16","author":"Engels","year":"1998","journal-title":"J Clin Oncol"},{"issue":"4","key":"10.1016\/j.blre.2025.101287_bb0435","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1093\/clinids\/23.4.795","article-title":"Prophylaxis with fluoroquinolones for bacterial infections in neutropenic patients: a meta-analysis","volume":"23","author":"Cruciani","year":"1996","journal-title":"Clin Infect Dis"},{"issue":"2","key":"10.1016\/j.blre.2025.101287_bb0440","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1111\/jcpt.13298","article-title":"Association of prior fluoroquinolone treatment with survival outcomes of immune checkpoint inhibitors in Asia","volume":"46","author":"Lu","year":"2021","journal-title":"J Clin Pharm Ther"},{"issue":"4","key":"10.1016\/j.blre.2025.101287_bb0445","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1038\/s41591-022-01702-9","article-title":"Gut microbiome correlates of response and toxicity following anti-CD19 CAR T cell therapy","volume":"28","author":"Smith","year":"2022","journal-title":"Nat Med"},{"key":"10.1016\/j.blre.2025.101287_bb0450","author":"Medicines and Healthcare products Regulatory Agency"},{"key":"10.1016\/j.blre.2025.101287_bb0455","author":"Agency EM"},{"key":"10.1016\/j.blre.2025.101287_bb0460","author":"National Institute for Health and Care Excellence"},{"issue":"5","key":"10.1016\/j.blre.2025.101287_bb0470","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1038\/sj.bjc.6602412","article-title":"An analysis of the utilisation of chemoprophylaxis against pneumocystis jirovecii pneumonia in patients with malignancy receiving corticosteroid therapy at a cancer hospital","volume":"92","author":"Worth","year":"2005","journal-title":"Br J Cancer"},{"issue":"4","key":"10.1016\/j.blre.2025.101287_bb0480","doi-asserted-by":"crossref","DOI":"10.1111\/tid.13114","article-title":"Early infectious complications after autologous hematopoietic cell transplantation for multiple myeloma","volume":"21","author":"Rahman","year":"2019","journal-title":"Transpl Infect Dis"},{"issue":"4","key":"10.1016\/j.blre.2025.101287_bb0490","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/S0002-9343(00)00725-7","article-title":"Late infections after blood progenitor cell transplantation in patients with multiple myeloma","volume":"110","author":"Steingrimsdottir","year":"2001","journal-title":"Am J Med"},{"issue":"9","key":"10.1016\/j.blre.2025.101287_bb0495","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1038\/sj.bmt.1704469","article-title":"Secondary antifungal prophylaxis with voriconazole to adhere to scheduled treatment in leukemic patients and stem cell transplant recipients","volume":"33","author":"Cordonnier","year":"2004","journal-title":"Bone Marrow Transplant"},{"issue":"6","key":"10.1016\/j.blre.2025.101287_bb0500","doi-asserted-by":"crossref","first-page":"e200","DOI":"10.1016\/S1473-3099(18)30600-5","article-title":"Vaccination of haemopoietic stem cell transplant recipients: guidelines of the 2017 European conference on infections in Leukaemia (ECIL 7)","volume":"19","author":"Cordonnier","year":"2019","journal-title":"Lancet Infect Dis"},{"issue":"25","key":"10.1016\/j.blre.2025.101287_bb0505","doi-asserted-by":"crossref","first-page":"3338","DOI":"10.1016\/j.vaccine.2021.04.049","article-title":"Safety and efficacy of early vaccination with live attenuated measles vaccine for hematopoietic stem cell transplant recipients and solid organ transplant recipients","volume":"39","author":"Groeneweg","year":"2021","journal-title":"Vaccine"},{"key":"10.1016\/j.blre.2025.101287_bb0510","author":"Haematology DoC, Oxford BMT\/ACT Programme"},{"issue":"1","key":"10.1016\/j.blre.2025.101287_bb0515","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/S1470-2045(18)30687-9","article-title":"Lenalidomide maintenance versus observation for patients with newly diagnosed multiple myeloma (myeloma XI): a multicentre, open-label, randomised, phase 3 trial","volume":"20","author":"Jackson","year":"2019","journal-title":"Lancet Oncol"},{"issue":"4","key":"10.1016\/j.blre.2025.101287_bb0520","doi-asserted-by":"crossref","DOI":"10.1042\/BSR20170304","article-title":"Efficacy and safety of bortezomib maintenance in patients with newly diagnosed multiple myeloma: a meta-analysis","volume":"37","author":"Sun","year":"2017","journal-title":"Biosci Rep"},{"issue":"8","key":"10.1016\/j.blre.2025.101287_bb0525","doi-asserted-by":"crossref","first-page":"1793","DOI":"10.1007\/s00277-020-04149-5","article-title":"Adverse event management in the TOURMALINE-MM3 study of post-transplant ixazomib maintenance in multiple myeloma","volume":"99","author":"Kaiser","year":"2020","journal-title":"Ann Hematol"},{"issue":"10","key":"10.1016\/j.blre.2025.101287_bb0530","doi-asserted-by":"crossref","first-page":"1378","DOI":"10.1016\/S1470-2045(21)00428-9","volume":"22","author":"Moreau","year":"2021","journal-title":"Lancet Oncol"},{"issue":"8","key":"10.1016\/j.blre.2025.101287_bb0535","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1056\/NEJMoa2024850","article-title":"Idecabtagene Vicleucel in relapsed and refractory multiple myeloma","volume":"384","author":"Munshi","year":"2021","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.blre.2025.101287_bb0540","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1056\/NEJMoa2203478","article-title":"Teclistamab in relapsed or refractory multiple myeloma","volume":"387","author":"Moreau","year":"2022","journal-title":"N Engl J Med"},{"issue":"Supplement 1","key":"10.1016\/j.blre.2025.101287_bb0545","doi-asserted-by":"crossref","first-page":"2003","DOI":"10.1182\/blood-2024-211410","article-title":"Cilta-Cel is associated with improved outcomes and distinct cellular dynamics compared with ide-Cel for relapsed or refractory multiple myeloma","volume":"144","author":"Gagelmann","year":"2024","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.blre.2025.101287_bb0550","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1016\/j.cmi.2024.02.023","article-title":"Characteristics and incidence of infections in patients with multiple myeloma treated by bispecific antibodies: a national retrospective study","volume":"30","author":"Jourdes","year":"2024","journal-title":"Clin Microbiol Infect"},{"issue":"12","key":"10.1016\/j.blre.2025.101287_bb0555","doi-asserted-by":"crossref","DOI":"10.1002\/cam4.7372","article-title":"Infections associated with CAR-T cell therapy in patients with relapsed refractory multiple myeloma: risks and prevention strategies","volume":"13","author":"An","year":"2024","journal-title":"Cancer Med"},{"issue":"9","key":"10.1016\/j.blre.2025.101287_bb0560","doi-asserted-by":"crossref","first-page":"2431","DOI":"10.1200\/JCO.1995.13.9.2431","article-title":"Infectious and immunosuppressive complications of purine analog therapy","volume":"13","author":"Cheson","year":"1995","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.blre.2025.101287_bb0565","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1111\/bjh.19668","article-title":"Mitigating infection risks: the promise and challenge of bispecific antibodies in haematological malignancies","volume":"205","author":"Rafei","year":"2024","journal-title":"Br J Haematol"},{"issue":"10","key":"10.1016\/j.blre.2025.101287_bb0570","doi-asserted-by":"crossref","first-page":"2181","DOI":"10.1038\/leu.2017.41","article-title":"Frequency of regulatory T cells determines the outcome of the T-cell-engaging antibody blinatumomab in patients with B-precursor ALL","volume":"31","author":"Duell","year":"2017","journal-title":"Leukemia"},{"issue":"8","key":"10.1016\/j.blre.2025.101287_bb0590","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1056\/NEJMoa2024850","article-title":"Idecabtagene Vicleucel in relapsed and refractory multiple myeloma","volume":"384","author":"Munshi Nikhil","year":"2021","journal-title":"New England Journal of Medicine."},{"issue":"11","key":"10.1016\/j.blre.2025.101287_bb0595","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1056\/NEJMoa2213614","article-title":"Ide-cel or standard regimens in relapsed and refractory multiple myeloma","volume":"388","author":"Rodriguez-Otero","year":"2023","journal-title":"New England Journal of Medicine."},{"issue":"6","key":"10.1016\/j.blre.2025.101287_bb0605","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1056\/NEJMoa2203478","article-title":"Teclistamab in relapsed or refractory multiple myeloma","volume":"387","author":"Moreau","year":"2022","journal-title":"New England Journal of Medicine"},{"issue":"Supplement 1","key":"10.1016\/j.blre.2025.101287_bb0610","first-page":"394","article-title":"Teclistamab in combination with subcutaneous Daratumumab and Lenalidomide in patients with multiple myeloma: results from one cohort of MajesTEC-2, a Phase1b","volume":"140","author":"Searle","year":"2022","journal-title":"Multicohort Study Blood"},{"issue":"24","key":"10.1016\/j.blre.2025.101287_bb0615","doi-asserted-by":"crossref","first-page":"2232","DOI":"10.1056\/NEJMoa2204591","article-title":"Talquetamab, a T-cell\u2013redirecting GPRC5D bispecific antibody for multiple myeloma","volume":"387","author":"Chari","year":"2022","journal-title":"New England Journal of Medicine."},{"issue":"Supplement 1","key":"10.1016\/j.blre.2025.101287_bb0620","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2023-187706","article-title":"Talquetamab + Pomalidomide in patients with relapsed\/refractory multiple myeloma: safety and preliminary efficacy results from the phase 1b MonumenTAL-2 study","volume":"142","author":"Matous","year":"2023","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.blre.2025.101287_bb0575","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1038\/s41375-020-0734-z","article-title":"B-cell maturation antigen (BCMA) in multiple myeloma: rationale for targeting and current therapeutic approaches","volume":"34","author":"Shah","year":"2020","journal-title":"Leukemia"},{"issue":"2","key":"10.1016\/j.blre.2025.101287_bb0580","doi-asserted-by":"crossref","first-page":"31","DOI":"10.46989\/001c.115932","article-title":"Managing infection complications in the setting of chimeric antigen receptor T cell (CAR-T) therapy","volume":"6","author":"Ahmed","year":"2024","journal-title":"Clin Hematol Int"},{"issue":"12","key":"10.1016\/j.blre.2025.101287_bb0585","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1016\/j.jtct.2021.09.016","article-title":"State of the CAR-T: risk of infections with chimeric antigen receptor T-cell therapy and determinants of SARS-CoV-2 vaccine responses","volume":"27","author":"Meir","year":"2021","journal-title":"Transplant Cell Ther"},{"issue":"1","key":"10.1016\/j.blre.2025.101287_bb0630","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1182\/blood-2017-07-793760","article-title":"Infectious complications of CD19-targeted chimeric antigen receptor-modified T-cell immunotherapy","volume":"131","author":"Hill","year":"2018","journal-title":"Blood"},{"issue":"Supplement 1","key":"10.1016\/j.blre.2025.101287_bb0635","doi-asserted-by":"crossref","first-page":"10073","DOI":"10.1182\/blood-2022-163733","article-title":"Infections and severe Hypogammaglobulinemia in multiple myeloma patients treated with anti-BCMA bispecific antibodies","volume":"140","author":"Lancman","year":"2022","journal-title":"Blood"},{"issue":"Suppl. 1","key":"10.1016\/j.blre.2025.101287_bb0640","article-title":"Vaccine schedule recommendations and updates for patients with hematologic malignancy post-hematopoietic cell transplant or CAR T-cell therapy","volume":"25","author":"Reynolds","year":"2023","journal-title":"Transpl Infect Dis"},{"issue":"1","key":"10.1016\/j.blre.2025.101287_bb0645","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1186\/s13045-020-01001-1","article-title":"Safety and clinical efficacy of BCMA CAR-T-cell therapy in multiple myeloma","volume":"13","author":"Roex","year":"2020","journal-title":"J Hematol Oncol"},{"issue":"8905","key":"10.1016\/j.blre.2025.101287_bb0650","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1016\/S0140-6736(94)90180-5","article-title":"Randomised trial of intravenous immunoglobulin as prophylaxis against infection in plateau-phase multiple myeloma. The UK Group for Immunoglobulin Replacement Therapy in multiple myeloma","volume":"343","author":"Chapel","year":"1994","journal-title":"Lancet"},{"issue":"6","key":"10.1016\/j.blre.2025.101287_bb0655","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1158\/2643-3230.BCD-23-0049","article-title":"IVIg use associated with ten-fold reduction of serious infections in multiple myeloma patients treated with anti-BCMA bispecific antibodies","volume":"4","author":"Lancman","year":"2023","journal-title":"Blood Cancer Discov"},{"issue":"7","key":"10.1016\/j.blre.2025.101287_bb0660","doi-asserted-by":"crossref","first-page":"2045","DOI":"10.1182\/bloodadvances.2020004079","article-title":"Infectious complications in patients with relapsed refractory multiple myeloma after BCMA CAR T-cell therapy","volume":"6","author":"Kambhampati","year":"2022","journal-title":"Blood Adv"},{"issue":"23","key":"10.1016\/j.blre.2025.101287_bb0665","doi-asserted-by":"crossref","first-page":"5290","DOI":"10.1182\/bloodadvances.2021004603","article-title":"Humoral immune reconstitution after anti-BCMA CAR T-cell therapy in relapsed\/refractory multiple myeloma","volume":"5","author":"Wang","year":"2021","journal-title":"Blood Adv"},{"issue":"10","key":"10.1016\/j.blre.2025.101287_bb0670","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1016\/j.clml.2023.05.008","article-title":"Recommendations for management of secondary antibody deficiency in multiple myeloma","volume":"23","author":"Giralt","year":"2023","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"2","key":"10.1016\/j.blre.2025.101287_bb0675","doi-asserted-by":"crossref","first-page":"297","DOI":"10.3324\/haematol.2019.229781","article-title":"Management of adults and children undergoing chimeric antigen receptor T-cell therapy: best practice recommendations of the European Society for Blood and Marrow Transplantation (EBMT) and the joint accreditation committee of ISCT and EBMT (JACIE)","volume":"105","author":"Yakoub-Agha","year":"2020","journal-title":"Haematologica"},{"issue":"5","key":"10.1016\/j.blre.2025.101287_bb0680","doi-asserted-by":"crossref","first-page":"e205","DOI":"10.1016\/S1470-2045(24)00043-3","article-title":"International myeloma working group immunotherapy committee consensus guidelines and recommendations for optimal use of T-cell-engaging bispecific antibodies in multiple myeloma","volume":"25","author":"Rodriguez-Otero","year":"2024","journal-title":"Lancet Oncol"},{"issue":"6","key":"10.1016\/j.blre.2025.101287_bb0685","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1038\/s41591-018-0036-4","article-title":"Monocyte-derived IL-1 and IL-6 are differentially required for cytokine-release syndrome and neurotoxicity due to CAR T cells","volume":"24","author":"Norelli","year":"2018","journal-title":"Nat Med"},{"issue":"6","key":"10.1016\/j.blre.2025.101287_bb0690","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1038\/s41591-018-0041-7","article-title":"CAR T cell-induced cytokine release syndrome is mediated by macrophages and abated by IL-1 blockade","volume":"24","author":"Giavridis","year":"2018","journal-title":"Nat Med"},{"issue":"24","key":"10.1016\/j.blre.2025.101287_bb0695","doi-asserted-by":"crossref","first-page":"2232","DOI":"10.1056\/NEJMoa2204591","article-title":"Talquetamab, a T-cell-redirecting GPRC5D bispecific antibody for multiple myeloma","volume":"387","author":"Chari","year":"2022","journal-title":"N Engl J Med"},{"issue":"13","key":"10.1016\/j.blre.2025.101287_bb0700","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.1056\/NEJMoa2209900","article-title":"GPRC5D-targeted CAR T cells for myeloma","volume":"387","author":"Mailankody","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.blre.2025.101287_bb0705","doi-asserted-by":"crossref","first-page":"4216","DOI":"10.1182\/blood-2018-99-120065","article-title":"Procalcitonin as a potential biomarker for differentiating bacterial infectious fevers from cytokine release syndrome","volume":"132","author":"Maakaron","year":"2018","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.blre.2025.101287_bb0710","doi-asserted-by":"crossref","first-page":"9228","DOI":"10.1002\/cam4.5665","article-title":"Procalcitonin as a biomarker for predicting bacterial infection in chimeric antigen receptor T-cell therapy recipients","volume":"12","author":"Powell","year":"2023","journal-title":"Cancer Med"},{"issue":"7","key":"10.1016\/j.blre.2025.101287_bb0715","doi-asserted-by":"crossref","first-page":"1642","DOI":"10.1038\/s41409-021-01226-9","article-title":"CRS-related coagulopathy in BCMA targeted CAR-T therapy: a retrospective analysis in a phase I\/II clinical trial","volume":"56","author":"Shao","year":"2021","journal-title":"Bone Marrow Transplant"},{"issue":"21","key":"10.1016\/j.blre.2025.101287_bb0720","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1182\/blood-2017-06-793141","article-title":"Kinetics and biomarkers of severe cytokine release syndrome after CD19 chimeric antigen receptor-modified T-cell therapy","volume":"130","author":"Hay","year":"2017","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.blre.2025.101287_bb0725","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1186\/s40164-024-00495-6","article-title":"Cytokine-based models for efficient differentiation between infection and cytokine release syndrome in patients with hematological malignancies","volume":"13","author":"Wang","year":"2024","journal-title":"Exp Hematol Oncol"},{"key":"10.1016\/j.blre.2025.101287_bb0730","author":"GOV.UK"},{"issue":"10","key":"10.1016\/j.blre.2025.101287_bb0735","doi-asserted-by":"crossref","first-page":"2465","DOI":"10.1080\/10428194.2018.1429605","article-title":"Use and impact of herpes zoster prophylaxis in myeloma patients treated with proteasome inhibitors","volume":"59","author":"Leng","year":"2018","journal-title":"Leuk Lymphoma"},{"issue":"3","key":"10.1016\/j.blre.2025.101287_bb0740","doi-asserted-by":"crossref","first-page":"e171","DOI":"10.1016\/j.clml.2022.12.003","article-title":"Rates of influenza and pneumococcal vaccination and correlation with survival in multiple myeloma patients","volume":"23","author":"Thompson","year":"2023","journal-title":"Clinical Lymphoma Myeloma and Leukemia"},{"issue":"3","key":"10.1016\/j.blre.2025.101287_bb0745","doi-asserted-by":"crossref","first-page":"155","DOI":"10.5001\/omj.2011.38","article-title":"Patient medication adherence: measures in daily practice","volume":"26","author":"Jimmy","year":"2011","journal-title":"Oman Med J"},{"issue":"4","key":"10.1016\/j.blre.2025.101287_bb0750","first-page":"18","article-title":"Understanding noncompliant behavior: definitions and causes","volume":"7","author":"Kleinsinger","year":"2003","journal-title":"Perm J"},{"issue":"10","key":"10.1016\/j.blre.2025.101287_bb0755","doi-asserted-by":"crossref","first-page":"1909","DOI":"10.1093\/annonc\/mdw266","article-title":"Is it best to expect the worst? Influence of patients\u2019 side-effect expectations on endocrine treatment outcome in a 2-year prospective clinical cohort study","volume":"27","author":"Nestoriuc","year":"2016","journal-title":"Ann Oncol"},{"issue":"5","key":"10.1016\/j.blre.2025.101287_bb0760","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1188\/19.CJON.540-542","article-title":"Shared decision making: improving patient outcomes by understanding the benefits of and barriers to effective communication","volume":"23","author":"Faiman","year":"2019","journal-title":"Clin J Oncol Nurs"},{"issue":"1","key":"10.1016\/j.blre.2025.101287_bb0765","doi-asserted-by":"crossref","first-page":"54","DOI":"10.7812\/TPP\/09-064","article-title":"Working with the noncompliant patient","volume":"14","author":"Kleinsinger","year":"2010","journal-title":"Perm J"}],"container-title":["Blood Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0268960X25000323?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0268960X25000323?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,6,8]],"date-time":"2025-06-08T04:22:23Z","timestamp":1749356543000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0268960X25000323"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7]]},"references-count":148,"alternative-id":["S0268960X25000323"],"URL":"https:\/\/doi.org\/10.1016\/j.blre.2025.101287","relation":{},"ISSN":["0268-960X"],"issn-type":[{"value":"0268-960X","type":"print"}],"subject":[],"published":{"date-parts":[[2025,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Practical guidance on the prevention and management of infection in multiple myeloma patients: A case-based approach","name":"articletitle","label":"Article Title"},{"value":"Blood Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.blre.2025.101287","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"101287"}}